Compare MYSE & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MYSE | INTS |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.2M | 13.7M |
| IPO Year | 2021 | 2021 |
| Metric | MYSE | INTS |
|---|---|---|
| Price | $1.37 | $3.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $19.33 |
| AVG Volume (30 Days) | ★ 26.9K | 18.4K |
| Earning Date | 11-16-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 56.64 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $550.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 26.15 | N/A |
| 52 Week Low | $1.37 | $0.22 |
| 52 Week High | $11.54 | $8.06 |
| Indicator | MYSE | INTS |
|---|---|---|
| Relative Strength Index (RSI) | 33.76 | 44.39 |
| Support Level | N/A | $3.10 |
| Resistance Level | $3.61 | $4.04 |
| Average True Range (ATR) | 0.10 | 0.24 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 10.46 | 55.17 |
Myseum.AI Inc is an integrate proprietary privacy-first artificial intelligence (AI) and social media technology company. The Company is developing privacy-first agentic localized AI agents to assist in managing personal media such as photos, videos and messages, while maintaining privacy.
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.